Angiodynamics: (NASD: ANGO)

$10.68

0.00 (0.00%)

Volume 58,979

May 17 04:00 PM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		10.57 - 10.73
	
		52wk Low - High
		9.52 - 12.91
	
		Previous Close
		10.68
	
		Avg. Volume
		106,427
	
		Industry
		MED INSTRUMENTS
	
		Market Cap
		374.33 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.66
	
		PE (Forward)
		31.72
	
		Current Year Est.
		0.34
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		114 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 04/17/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            31.72
                        
                            PEG Ratio
                            2.11
                        
                            Current Year Est.
                            0.34
                        
                            Current Quarter Estimate
                            0.05
                        
                            Most Accurate Estimate
                            0.05
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-11-2013
                        
                            EPS Last Year
                            0.38
                        
                            Expected Earnings Growth
                            15.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products.   
Full ANGO Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ANGO Chart  by YCharts

Earnings Estimates

	Current Qtr (05/2013)	Next Qtr (08/2013)	Current Year (05/2013)	Next Year (05/2014)
Average Estimate	0.05	0.07	0.34	0.31
Number of Estimates	2	1	3	2
Low Estimate	0.05	0.07	0.33	0.25
High Estimate	0.05	0.07	0.34	NA
Year Ago EPS	0.10	0.10	0.43	0.34
EPS Growth	-50.00%	-30.00%	-21.71%	-7.92%

More ANGO Estimates

Average Earnings Estimates for ANGO

EPS Growth for ANGO

Industry Analysis

Name	Symbol	Previous Close
ANGIODYNAMICS	ANGO	10.68
NATUS MEDICAL	BABY	14.36
CRYOLIFE INC	CRY	6.34
DELCATH SYS INC	DCTH	0.41
GLOBUS MEDICAL	GMED	15.69
HEARTWARE INTL	HTWR	99.19
MELA SCIENCES	MELA	1.07
OXYSURE SYSTEMS	OXYS	0.90
PACIFIC BIOSCI	PACB	2.42
SUNSHINE HEART	SSH	5.49

Sector:Medical>> Industry:MED INSTRUMENTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Bearish MACD for AngioDynamics, Inc.

Apr 25, 2013

Company News for April 10, 2013

Apr 10, 2013

ANGO Posts Dismal 3Q Earnings

Apr 09, 2013

Angio Posts Dismal Prelim Results

Mar 08, 2013

Angio Closes Microsulis Deal

Feb 04, 2013

ANGO and Microsulis Work Out Deal

Jan 24, 2013

ANGO Beats on EPS, Tweaks View

Jan 04, 2013

CR Bard Remains Neutral

Dec 06, 2012

More ANGO Zacks Commentary

Financials

EPS TTM	0.38
Sales	222
Net Income	-7
Price/Earnings	28.11
Price/Book	0.71
Price/Cash Flow	10.88
Price/Sales	1.21

More ANGO Financials

News

AngioDynamics to Present at UBS Global Healthcare Conference - Globenewswire

May 14, 2013

PKH, BMC, VVUS, PDS, ANGO, WBCO Are Seasonally Ripe To Go Up In the Next Five Weeks - M2

May 3, 2013

Stock Investors Bid Up Shares of Angiodynamics, Up 1.8% - Financial News Network Online - Market Movers

Apr 24, 2013

Angiodynamics: The Losing Streak Continues (ANGO) - Financial News Netwfork Online - 52-Week High-Lows

Apr 22, 2013

Buyers Accumulate Shares of Angiodynamics, Up 2.1% - Financial News Network Online - Market Movers

Apr 19, 2013

How Quickly Is the Cash Coming at AngioDynamics? - TheMotleyFool

Apr 18, 2013

Shares of Angiodynamics Have Fallen Below Previous 52-Week Low - Financial News Netwfork Online - 52-Week High-Lows

Apr 18, 2013

Here`s Why AngioDynamics`s Latest Report Might Worry You - TheMotleyFool

Apr 16, 2013

See All News Stories on ANGO

Broker Recommendations

Current ABR	2.33
ABR (Last Week)	2.33
# of recs in ABR	6
Average Target Price	12.30
Industry Rank by ABR	114 out of 265
Rank in Industry	44 out of 52

More ANGO Broker Recommendations

Day Low - High	10.57 - 10.73
52wk Low - High	9.52 - 12.91
Previous Close	10.68
Avg. Volume	106,427
Industry	MED INSTRUMENTS
Market Cap	374.33 M
Div - Yield	0.00 - 0.00
Beta	0.66
PE (Forward)	31.72
Current Year Est.	0.34
Quarterly Earnings ESP	0.00%

PE (Forward)	31.72
PEG Ratio	2.11
Current Year Est.	0.34
Current Quarter Estimate	0.05
Most Accurate Estimate	0.05
Earnings ESP	0.00%
Next Earnings Report Date	07-11-2013
EPS Last Year	0.38
Expected Earnings Growth	15.00%

Username: Password:

Remember me [?]

Angiodynamics: (NASD: ANGO)

$10.68

0.00 (0.00%)

Volume 58,979

May 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description